Long‐term outcome of 2‐year survivors after allogeneic hematopoietic cell transplantation for acute leukemia
Open Access
- 22 October 2024
- journal article
- research article
- Published by Wiley in HemaSphere
- Vol. 8 (10) , e70026
Abstract
Information on late complications in patients with acute leukemia who have undergone allogeneic hematopoietic cell transplantation (HCT) is limited. We performed a left‐truncated analysis of long‐term survival in patients with acute leukemia who were alive and disease‐free 2 years after HCT. We included 2701 patients with acute lymphoblastic leukemia (ALL) and 9027 patients with acute myeloid leukemia (AML) who underwent HCT between 2005 and 2012. The 10‐year overall survival (OS) rate was 81.3% for ALL and 76.2% for AML, with the main causes of late mortality being relapse (ALL‐33.9%, AML‐44.9%) and chronic graft‐versus‐host disease (ALL‐29%, AML‐18%). At 10 years, HCT‐related mortality was 16.8% and 20.4%, respectively. Older age and unrelated donor transplantation were associated with a worse prognosis for both types of leukemia. In addition, transplantation in the second or third complete remission and peripheral blood HSC for ALL are associated with worse outcomes. Similarly, adverse cytogenetics, female donor to male patient combination, and reduced intensity conditioning in AML contribute to poor prognosis. We conclude that 2‐year survival in remission after HCT for acute leukemia is encouraging, with OS of nearly 80% at 10 years. However, the long‐term mortality risk of HCT survivors remains significantly higher than that of the age‐matched general population. These findings underscore the importance of tailoring transplantation strategies to improve long‐term outcomes in patients with acute leukemia undergoing HCT.Keywords
This publication has 84 references indexed in Scilit:
- Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-BBlood, 2006
- Age and acute myeloid leukemiaBlood, 2006
- Relative survival analysis in RComputer Methods and Programs in Biomedicine, 2006
- The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantationBlood, 2001
- Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusionsLeukemia, 2001
- Long-Term Survival and Late Deaths after Allogeneic Bone Marrow TransplantationNew England Journal of Medicine, 1999
- INDUCTION OF INVITRO GRAFT-VERSUS-LEUKEMIA ACTIVITY FOLLOWING BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA1990
- PREDICTIVE FACTORS FOR ACUTE GRAFT-VERSUS-HOST DISEASE IN PATIENTS TRANSPLANTED WITH HLA-IDENTICAL BONE-MARROW1984
- A Randomized Study of the Prevention of Acute Graft-versus-Host DiseaseNew England Journal of Medicine, 1982
- Treatment of 144 patients with severe aplastic anemia using immunosuppression and allogeneic marrow transplantation: a report from the international bone marrow transplant registry.1981